ABSTRACT
Background Transmission bottlenecks are defined by the number of unique virions or genotypes that establish an infection, and they restrict the viral diversity that passes from one infected host to another. They have a major impact on the spread of mutations in a population. Previous work has identified a tight transmission bottleneck for seasonal influenza A virus (IAV) based on an analysis of 43 household pairs, largely from a single A(H3N2) predominant season. While many viral and host factors are known to influence IAV transmission in households, their impact on the transmission bottleneck is not clear.
Methods Nasal swabs were collected daily from IAV infected individuals enrolled in two case-ascertained U.S. household transmission studies, FluTES (2017/2018 through 2019/2020 seasons) and RVTN (2021/2022 season). Viruses were sequenced in duplicate, and intrahost single nucleotide variants (iSNV) were identified at a 0.5% frequency threshold using a benchmarked pipeline with >99.99% specificity for mutations present in both replicates. Transmission pairs were defined based on co-residence, test date, and genetic distance. For each possible transmission pair, the bottleneck was estimated using a beta binomial and a clonal mutation model.
Results We sequenced 567 samples from 319 individuals and 102 households in duplicate. Based on epidemiologic linkage and a sequence-based cut-off, we defined 56 transmission pairs for the beta binomial model and 60 transmission pairs for the clonal mutation model. Across all pairs, we identified a transmission bottleneck of 1 both using the beta-binomial model (CI 1, 1) and the clonal mutation model (exact estimate: 0.91, CI: 0.91, 0.97). In our cohort, influenza season, subtype, and host factors (influenza vaccination status, sex, and age) did not alter the transmission bottleneck.
Conclusions IAV is subject to a tight genetic bottleneck during transmission, which limits the onward propagation of newly arising nucleotide variants. Tight bottlenecks appear to be intrinsic to the transmission process, as host and viral factors within households do not affect its size.
Competing Interest Statement
ASL reports consulting fees and research support from Roche related to analyses of transmission in the CENTERSTONE trial of baloxavir. HQN reports receiving research support from CSL Seqirus, GSK, and Moderna outside the submitted work.
Funding Statement
KK was supported by the Molecular Mechanisms in Microbial Pathogenesis Training Program, NIH T32 AI007528. The FluTES study was supported by CDC U01IP001083 (to HKT, CGG) and the RVTN-S study was supported by CDC 75D30121C11656 (to HKT, CGG). Sequencing and analysis in the Lauring lab was supported by NIH R01 AI148371 (to ASL, ETM) and Penn-CEIRR, NIH 75N93021C00015 (to ASL, ETM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These studies were approved by the Vanderbilt University Medical Center Institutional Review Board (FluTES IRB #171420, RVTN-S IRB #211495), reviewed by CDC, and conducted consistent with applicable federal law and CDC policy (45 CFR 46.102(l)(2)). All adults provided written consent; for children, parents provided written permission and children ≤ 7 years old provided assent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
